leisure time -WSS

leisure time

author：explore 2025-08-12 08:27:41 - browse：85778

Sammy Kimball for STAT

Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： NEJM study measures Covid brain fog, impact on IQ

entertainment

WSS

FDA authorizes Novavax’s updated Covid

Medicare isn't yet testing food as medicine

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

3 questions for the future of Biden's cancer moonshot

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

What to expect at HLTH 2023, the health care industry conference

knowledge

leisure time

leisure time

Activists slam private health insurers over coverage restrictions

Why Charlie Gard's case is so disturbing to Americans

As demand for Covid shots wanes, Moderna seeks its next success

Chemotherapy drug shortage eases slightly but still widespread

Virginia high school admissions case could be legal follow

Was Amgen transparent enough on FDA's concern on cancer drug?

Activists slam private health insurers over coverage restrictions

Why age limits for politicians are a terrible idea

After affirmative action ruling, medical educators look to 'holistic review'

VC firm General Catalyst wants to buy a health system

hotspot

Stroke deaths set to near 10 million globally by 2050

Medicare Advantage isn’t working — for anyone

FDA rejects Alnylam's heart disease treatment over insufficient data

AI can decode, harness the power of the humane immune system

When women are denied an abortion, their children fare worse than peers

Are embryos people? Reproductive medicine's future depends on the answer

focus

entertainment

leisure time

knowledge